A Phase 2, Pilot, Multicenter, Randomized, Placebo-Controlled Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Activity of CC-930 in Subjects With Recalcitrant Discoid Lupus Erythematosus (DLE).

Trial Profile

A Phase 2, Pilot, Multicenter, Randomized, Placebo-Controlled Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Activity of CC-930 in Subjects With Recalcitrant Discoid Lupus Erythematosus (DLE).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs Tanzisertib (Primary)
  • Indications Discoid lupus erythematosus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Jul 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 10 Nov 2011 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top